IQVIA Connected Devices provides customized solutions to accelerate clinical development and commercialization in diabetes trials with enhanced glucose data collection, closer to the patient. IQVIA has provided >23K CGM devices to support clinical development in 36 countries since 2016, surrounding trials with a team of experts to provide end-to-end solutions for CGM studies using a range of approved devices.
Clinical trials face increasing pressure to deliver new treatments to market faster. IQVIA Connected Devices accelerates trial outcomes with medical device recommendations that fit your clinical study, deliver cleaner data, and speed data collection and analysis with lower patient and site burdens.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
.svg){kind=icon}
